• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    9/6/22 8:15:20 AM ET
    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ALNA alert in real time by email

     

    Gainers

    • IVERIC bio (NASDAQ:ISEE) stock increased by 35.7% to $12.81 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion.
    • Organovo Holdings (NASDAQ:ONVO) stock increased by 20.99% to $2.79. The market value of their outstanding shares is at $24.3 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares rose 18.86% to $3.78. The market value of their outstanding shares is at $5.2 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 16.53% to $0.64. The market value of their outstanding shares is at $13.9 million.
    • Rubius Therapeutics (NASDAQ:RUBY) shares increased by 15.62% to $1.07. The company's market cap stands at $96.6 million.
    • GlycoMimetics (NASDAQ:GLYC) stock increased by 15.58% to $0.85. The market value of their outstanding shares is at $44.5 million.

    Losers

    • Allena Pharma (NASDAQ:ALNA) shares declined by 23.6% to $0.08 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.7 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares decreased by 13.76% to $12.85. The company's market cap stands at $170.6 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares decreased by 9.22% to $0.19. The market value of their outstanding shares is at $6.0 million.
    • Scopus BioPharma (NASDAQ:SCPS) stock fell 8.71% to $0.33. The company's market cap stands at $6.8 million.
    • Bright Green (NASDAQ:BGXX) shares decreased by 8.67% to $1.37. The market value of their outstanding shares is at $218.9 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock decreased by 7.77% to $0.31. The market value of their outstanding shares is at $22.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNA
    $BGXX
    $FWBI
    $GLYC

    CompanyDatePrice TargetRatingAnalyst
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    KALA BIO Inc.
    $KALA
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    GlycoMimetics Inc.
    $GLYC
    3/21/2025Overweight
    Cantor Fitzgerald
    GlycoMimetics Inc.
    $GLYC
    7/26/2024Buy → Hold
    TD Cowen
    GlycoMimetics Inc.
    $GLYC
    12/22/2023$12.00Overweight
    CapitalOne
    More analyst ratings

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KALA BIO downgraded by Mizuho with a new price target

    Mizuho downgraded KALA BIO from Outperform to Neutral and set a new price target of $1.50

    9/30/25 9:48:28 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by H.C. Wainwright

    H.C. Wainwright downgraded KALA BIO from Buy to Neutral

    9/29/25 1:25:35 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded KALA BIO from Buy to Neutral

    9/29/25 9:48:46 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IZERVAY issued to IVERIC BIO, INC.

    Submission status for IVERIC BIO, INC.'s drug IZERVAY (ORIG-1) with active ingredient AVACINCAPTAD PEGOL has changed to 'Approval' on 08/04/2023. Application Category: NDA, Application Number: 217225, Application Classification: Type 1 - New Molecular Entity

    8/9/23 8:37:19 AM ET
    $ISEE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Purdy Brendan P.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:24 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Berger Chaim D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:15:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Posen Hillel D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    SEC Filings

    View All

    SEC Form 8-K filed by KALA BIO Inc.

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    2/20/26 4:05:55 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by KALA BIO Inc.

    EFFECT - KALA BIO, Inc. (0001479419) (Filer)

    2/18/26 12:15:36 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by KALA BIO Inc.

    424B3 - KALA BIO, Inc. (0001479419) (Filer)

    2/17/26 4:44:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith

    Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel's Failure Cibola County, New Mexico, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXXQ) and its Chief Executive Officer, Lynn Stockwell, today announced the filing of a landmark lawsuit seeking damages in excess of $3 billion against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS). The complaint, filed in the Thirteenth Judicial District Court of New Mexico, alleges legal malpractice, breach of contract, and bad faith breach of fiduciary duty. The underlying litigation resulted in findings of no wrongdoing by Lynn Stockwell. Despite this, the court

    1/8/26 9:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    KALA BIO Settles Approximately $10.6 million of Debt

    ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), ("KALA" or the "Company") today announced the successful completion of its loan settlement with Oxford Finance, LLC ("Oxford"), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations. As previously disclosed in the Company's Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford $2 million to be paid pursuant to the terms of the Settlement Agreement. The Settlement Agreement was negotiated in connection with

    1/5/26 4:10:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    12/31/24 4:00:18 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    6/24/24 4:29:48 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), increasing direct ownership by 33% to 70,643 units (SEC Form 4)

    4 - GLYCOMIMETICS INC (0001253689) (Issuer)

    6/20/24 4:15:39 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Organovo Holdings Inc.

    SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

    11/14/24 3:34:49 PM ET
    $ONVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Leadership Updates

    Live Leadership Updates

    View All

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Appoints David Lubner to Board of Directors

    Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

    4/28/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ALNA
    $BGXX
    $FWBI
    $GLYC
    Financials

    Live finance-specific insights

    View All

    GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

    Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

    10/29/24 7:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

    6/4/24 7:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

    5/6/24 6:00:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care